Effect of gefitinib challenge to initial treatment with non-small cell lung cancer

Biomedicine and Pharmacotherapy

Volumn 65, Issue 8, 2011, Pages 542-546

  Chen, Xiaofeng ^a   Li, Wei ^a   Hu, Xiaoli ^a   Geng, Yiting ^a   Wang, Rong ^a   Yin, Yongmei ^a   Shu, Yongqian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

First line treatment; Gefitinib; Non small cell lung cancer (NSCLC)

Indexed keywords

GEFITINIB; VASCULOTROPIN RECEPTOR 1;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; DEHYDRATION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; FEMALE; HUMAN; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; PRIORITY JOURNAL; PRURITUS; SEQUENCE ANALYSIS; SURVIVAL RATE; TOXICITY TESTING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; REMISSION INDUCTION; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 82755197887     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.04.017     Document Type: Article

References (14)

1. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of Gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003, 21(12):2237-2246.
2. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib an inhibitor of the epidermal growth factor receptor tyrosine kinase in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290(16):2149-2158.
3. Niho S., Kubota K., Goto K., Yoh K., Ohmatsu H., Kakinuma R., et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 2006, 24(1):64-69.
4. D'Addario G., Rauch D., Stupp R., Pless M., Stahel R., Mach N., et al. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol 2008, 19(4):739-745.
5. Ebi N., Semba H., Tokunaga S.J., Takayama K., Wataya H., Kuraki T., et al. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol 2008, 3(10):1166-1171.
6. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):205-216.
7. Hollen P.J., Gralla R.J., Kris M.G., Potanovich L.M. Quality of life assessment in individuals with lung cancer: testing the lung cancer symptom scale (LCSS). Eur J Cancer 1993, 29A(Suppl. 1):S51-S58.
8. Shun Lu, Ziming Li. Targeted therapy of lung cancer-data from Asia. China Oncol 2007, 17(1):8-13.
9. Yang C.H., Shih J.Y., Chen K.C., Yu C.J., Yang T.Y., Lin C.P., et al. Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced non-small cell lung cancer. Cancer 2006, 107(8):1873-1882.
10. Tony Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Datong Chu, Nagahiro Saijo, et al. Phase III, randomised, open-label, first-line study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced non small cell lung cancer (IPASS). Ann Oncol 2008;19:viii, [ESMO abstract].
11. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
12. Yamamoto H., Toyooka S., Mitsudomi T. Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer 2009, 63(3):315-321.
13. Mu X.L., Li L.Y., Zhang X.T., Wang M.Z., Feng R.E., Cui Q.C., et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Clin Cancer Res 2005, 11(12):4289-4294.
14. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Jänne P.A., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26:2442-2449.